Survodutide, a drug developed by Boehringer Ingelheim and Zealand Pharma, showed success in treating a serious liver condition called MASH in a Phase 2 study. The drug resulted in significant improvements in 83% of patients compared to 18% in the placebo group without worsening fibrosis. Zealand Pharma’s stock price doubled over the past year due to the drug’s potential, with shares increasing by 25% after the announcement. Secondary endpoints, including an improvement in fibrosis, were also met in the study. This success comes amidst increasing competition in the obesity medicine field, with survodutide showing promise as a weight loss treatment.
Source link
With competition flaring, obesity drug hits goal in liver disease study
